Abstract:The glucose transporter family (GLUT) consists of fourteen members. It is responsible for glucose homeostasis and glucose transport from the extracellular space to the cell cytoplasm to further cascade catalysis. GLUT proteins are encoded by the solute carrier family 2 (SLC2) genes and are members of the major facilitator superfamily of membrane transporters. Moreover, different GLUTs also have their transporter kinetics and distribution, so each GLUT member has its uniqueness and importance to play essential roles in human physiology. Evidence from many studies in the field of diabetes showed that GLUT4 travels between the plasma membrane and intracellular vesicles (GLUT4-storage vesicles, GSVs) and that the PI3K/Akt pathway regulates this activity in an insulin-dependent manner or by the AMPK pathway in response to muscle contraction. Moreover, some published results also pointed out that GLUT4 mediates insulin-dependent glucose uptake. Thus, dysfunction of GLUT4 can induce insulin resistance, metabolic reprogramming in diverse chronic diseases, inflammation, and cancer. In addition to the relationship between GLUT4 and insulin response, recent studies also referred to the potential upstream transcription factors that can bind to the promoter region of GLUT4 to regulating downstream signals. Combined all of the evidence, we conclude that GLUT4 has shown valuable unknown functions and is of clinical significance in cancers, which deserves our in-depth discussion and design compounds by structure basis to achieve therapeutic effects. Thus, we intend to write up a most updated review manuscript to include the most recent and critical research findings elucidating how and why GLUT4 plays an essential role in carcinogenesis, which may have broad interests and impacts on this field.

Development of Glucose Transporter (GLUT) Inhibitors

Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach

GLUT1: a Promising Drug Target for Cancer Treatment

Glucose transporters in cancer – from tumor cells to the tumor microenvironment

The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism

Identification of Novel Inhibitors of GLUT1 by Virtual Screening and Cell-Based Assays

Computer-assisted Identification of Novel Small Molecule Inhibitors Targeting GLUT1

SGLT2 Inhibitors as Potential Anticancer Agents

GLUT3 inhibitor discovery through in silico ligand screening and in vivo validation in eukaryotic expression systems

Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression

Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus.

Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies

Ligand-based Design of GLUT Inhibitors As Potential Antitumor Agents

Identification of a Novel GLUT1 Inhibitor with in Vitro and in Vivo Anti-Tumor Activity.

Molecular basis for inhibiting human glucose transporters by exofacial inhibitors

Progress on Glucosidase Inhibitors

Structural Aspects of the Glucose and Monocarboxylate Transporters Involved in the Warburg Effect

Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus

DDIS-24. DECREASE IN GLIOBLASTOMA GROWTH IN VITRO WITH TREATMENT OF NOVEL ANALOGS OF GLUCOSE TRANSPORTER INHIBITORS

Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus